Clinical Trials for Colon Cancer

Safety and Efficacy of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian, Uterine, Appendiceal, Colorectal, and Gastric Cancer Patients With Peritoneal Carcinomatosis (PC)

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with peritoneal carcinomatosis from ovarian, uterine, gastric, appendiceal, or colorectal cancer who have progressed after at least one prior chemotherapy, testing the safety and efficacy of PIPAC (pressurized intraperitoneal aerosol chemotherapy) with standard agents (doxorubicin/cisplatin, oxaliplatin, or mitomycin plus FOLFIRI) according to tumor type and prior treatment. PIPAC aims to enhance local drug exposure in the peritoneum while potentially reducing systemic toxicity.

ClinicalTrials.gov ID: NCT04329494

A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with unresectable or metastatic colorectal adenocarcinoma lacking RAS, RAF, EGFR, and ERBB2 alterations, and evaluates the bispecific EGFR/MET antibody amivantamab (which blocks both receptors and recruits immune effector cells) as monotherapy or in combination with standard mFOLFOX6 or FOLFIRI chemotherapy. Patients with symptomatic CNS disease are excluded.

ClinicalTrials.gov ID: NCT05379595

A Phase I, Open-label, Non-randomised, Multi-center Dose Escalation Trial of BI 765049 Administered by Parenteral Route in Patients With Advanced, Unresectable, and/or Metastatic Colorectal Carcinoma (CRC), Gastric Carcinoma (GC), or Pancreatic Ductal Adenocarcinoma (PDAC) to Determine the MTD and the RP2D and to Determine the Dosing Regimen for Further Development of BI 765049

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced, unresectable or metastatic colorectal, gastric, or pancreatic ductal adenocarcinoma after prior treatment failure or with no available treatment receive parenteral BI 765049 on one of two dosing regimens; European enrollment is limited to colorectal cancer. BI 765049 is a bispecific antibody that binds B7-H6 on tumor cells and CD3 on T cells to promote tumor-cell killing.

ClinicalTrials.gov ID: NCT06882746

A Phase I Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with unresectable or metastatic colorectal adenocarcinoma progressing after at least two prior lines of standard therapy, ECOG 0–1, and adequate renal function receive JNJ-89402638 in dose-escalation or dose-expansion cohorts. The agent’s target and mechanism are not reliably established.

ClinicalTrials.gov ID: NCT06663319

A Phase I Study of Trifluridine/ Tipiracil Plus the Poly (ADP) Ribose Polymerase Inhibitor Talazoparib in Advanced Cancers

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Eligible patients have advanced or metastatic colorectal or gastroesophageal adenocarcinoma with prior treatment failure, and will receive oral trifluridine/tipiracil plus talazoparib, a PARP inhibitor targeting DNA repair, to evaluate safety and dosing. Certain biomarker-defined cohorts are also included.

ClinicalTrials.gov ID: NCT04511039

A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Eligible patients are adults with metastatic or unresectable solid tumors harboring a G12V mutation in KRAS, NRAS, or HRAS who are HLA-A*11:01 positive and have progressed on or declined standard therapies. Treatment involves lymphodepleting chemotherapy followed by infusion of autologous peripheral blood lymphocytes genetically modified to express a murine T-cell receptor targeting the G12V RAS mutation, along with high-dose aldesleukin.

ClinicalTrials.gov ID: NCT03190941

A Phase 1, First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC028 in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable, unresectable locally advanced or metastatic NSCLC adenocarcinoma, cholangiocarcinoma, colorectal cancer, or pancreatic cancer after standard therapy or without a suitable standard option receive intravenous MGC028. This investigational ADAM9-targeted antibody–drug conjugate delivers exatecan, a topoisomerase I inhibitor.

ClinicalTrials.gov ID: NCT06723236

A Phase I/IIa Image-Guided, Alpha-Particle Therapy Study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in Patients With Solid Tumors That Are Known to be Fibroblast Activation Protein (FAP)-Positive

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors that have progressed after standard therapy or lack a standard option are eligible if at least one lesion shows uptake on [203Pb]Pb-PSV359 SPECT/CT. The imaging agent selects patients for treatment with [212Pb]Pb-PSV359, a FAP-targeted peptide that delivers alpha-particle radiation.

ClinicalTrials.gov ID: NCT06710756

An Open-label, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumour Activity of WEF-001 in Participants With Advanced KRAS- Mutant Solid Tumours.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with measurable, progressive KRAS-mutant pancreatic, colorectal, lung, platinum-resistant serous ovarian, cholangiocarcinoma, or urothelial bladder cancer after at least one standard therapy receive intravenous WEF-001 monotherapy. WEF-001 is investigational and is proposed to exploit macropinocytosis in KRAS-mutant tumors; direct KRAS inhibition has not been established.

ClinicalTrials.gov ID: NCT07148128

A Phase 1 Study of ASP5834 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS Mutations or KRAS Amplifications

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic solid tumors harboring specified KRAS mutations or eligible KRAS amplification receive intravenous ASP5834, an investigational agent designed to degrade mutant or amplified KRAS. Patients with KRAS-mutated colorectal adenocarcinoma may receive ASP5834 with panitumumab, an anti-EGFR antibody.

ClinicalTrials.gov ID: NCT07094204